-
NADDI 34th Annual Conference
October 24, 2023
8:00 am - 5:00 pm -
NADDI 34th Annual Conference
October 25, 2023
8:00 am - 5:00 pm -
NADDI 34th Annual Conference
October 26, 2023
8:00 am - 5:00 pm -
NADDI 34th Annual Conference
October 27, 2023
8:00 am - 12:00 pm
NADDI 34th Annual Conference
October 24-27, 2023
Hilton Myrtle Beach
Be part of NADDI’s 34th Annual Conference where solutions are formulated and stakeholders from across the United States convene to partner and collaborate. Join the discussion addressing a fentanyl crisis and an epidemic of overdose deaths by joining us in Myrtle Beach, SC.
Keynote Speaker
Anne Milgram, Administrator
Drug Enforcment Administration
*You do not have to be a NADDI member to attend. All attendees who qualify for membership will receive a complimentary one year membership. Current members receive an additional one year membership.
Sponsors and Exhibitors
Protenus – Gold Sponsor/Exhibitor
Detechtachem – Exhibitor
Guidepost Solutions – Silver Sponsor/Exhibitor
Invistics/Wolters Kluwer – Silver Sponsor/Exhibitor
Partnership for Safe Medicines – Silver Sponsor
Priority Ambulance – Silver Sponsor/Exhibitor
R Street – Exhibitor
Shatterproof – Exhibitor
Victoria’s Voice Foundation – Silver Sponsor/Exhibitor
*For sponsorship/exhibitor opportunies, please contact Charlie ccichon@naddi.org
Monday, October 23rd
Noon
NADDI Annual Board of Directors Meeting
4:00pm – Pallisades Corridor
Early Registration
Exhibitor Set-up
8:00pm
Monday Night Football Welcome Reception
49ers at Vikings
Tuesday, October 24, 2023
Pallisades Ballroom
8:00 am – 5:00 pm – General Session
Myrtle Beach Police Department Honor Guard
The Pleadge of Allegiance
Welcoming Remarks
Chief Amy Prock, Myrtle Beach Police Department
Keynote Speaker
DEA Administrator Anne Milgram
Opioid Enforcement Cases – Ruan Supreme Court Decision and Changes in CDC Guidelines on Prescribing Opioids
Paul Lynch, MD, DABA
Ruan v United States, 20-1410. The Court held that once a doctor who is charged with dispensing controlled substances produces evidence that his conduct was “authorized,” the Government must prove beyond a reasonable doubt that the doctor knowingly or intentionally acted in an unauthorized manner.
The Diversion Dilemma: Which Side Are You On?
Rodrigo Garcia, MBA. MSN, APN-BC, CRNA
Parkdale CEO, Diversion Consultant
Claudia Garcia, MBA, BSN, RN, CADAC II, LAC
Parkdale COO, Diversion Consultant
Terri Vidals, BS Pharm
Drug Diversion Prevention Specialist
Rxpert Solutions
Diversion programs vary from facility to facility. Some of that diversity is related to how the leadership views the seriousness or risks of diversion. The panel will discuss various controversial topics with the goal of presenting more than one perspective.
Disguised by Design: A 2023 Update on Emerging New Potent Synthetic Opioids
Donna Papsun, D-ABFT-FT, Forensic Toxicologist
NMS Labs
Novel Psychoactive Substances (NPS)
Compounds are either repurposed from pharmaceutical research or chemically modified by other drugs of abuse
“FENTANYL KILLS”
Louisiana BCBS Fentanyl Awareness Video
Kandyce Cowart, NADDI Lousiana Chapter President
Wednesday, October 25, 2023
Pallisades Ballroom
8:00 am – 5:00 pm – General Session
Police, Treatment, and Community Collaborative (PTACC)
Jac Charlier, Executive Director
Jillian Snider, R Street
Policy Director
Ctiminal Justice and Civil Liberties
PTACC is the definitive voice in the field of deflection and pre-arrest diversion. PTACC provides vision, leadership, advocacy, and education to facilitate the growth and practice of deflection and pre-arrest diversion.
IPR Center Partners with Pharmaceutical Security Institute (PSI)
to Prevent Fake Drugs
Todd Ratcliffe, Executive Director
Pharmacutical Security Institute
Jim Mancuso, Director, IPR Center
The National Intellectual Property Rights Coordination Center (IPR Center) announced a new partnership between Homeland Security Investigations (HSI) and the Pharmaceutical Security Institute (PSI) to combat illicit pharmaceutical trade and protect patients from the health and safety threats posed by counterfeit medications.
Human Trafficking and Rx Drugs
Panel Discussion
Trafficking of illegal drugs and human trafficking often happen together. Transnational drug traffickers and criminal organizations often look to increase profits and market control through diversification. This means using trafficking routes for drugs, labor, sex, and violence. Transporting people (usually women and children) for sex is just another egregious source of profits for these violent criminals.
Operation Overdrive
Jarod A. Forget, Special Agent in Charge – Washington Field Division
Drug Enforcement Administration
The Drug Enforcement Administration announced a new initiative, Operation Overdrive, aimed at combatting the rising rates of drug-related violent crime and overdose deaths plaguing American communities. Last fall, DEA initiated a data-driven approach using national crime statistics and CDC data to identify hot spots of drug-related violence and overdose deaths across the country, in order to devote its law enforcement resources to where they will have the most impact: the communities where criminal drug networks are causing the most harm.
Evolution of Drug Diversion Technologies in the Hospital Setting
Danielle Neal, PharmD, MBA, BCPS, CPEL, DPLA
Pharmacy Compliance and Drug Diversion
Compliance & Integrity Department
Advocate Health
Leah Mitchell, PharmD, MBA
Program Director
Controlled Substance Compliance and Drug Diversion
Advocate Health
Drug diversion is a growing problem in healthcare facilities worldwide, particularly due to the accessibility of medications to staff members. While it may seem victimless, drug diversion can wreak havoc on healthcare facilities and patients.
Thursday, October 26, 2023
Pallisades Ballroom
8:00 am – 5:00 pm – General Session
Disrupting Illegal Online Pharmacies
NABP Lock-and-Suspend Program
Justin Macy and Niamh Lewis NABP
Lock-and-suspend renders dangerous websites immediately unreachable through the DNS and directly impacts patient safety. Because most illegal online pharmacies belong to large criminal networks that operate thousands of domain names in redundancy, to be effective, action must be taken at scale.
FDA OCI Cybercrime Investigations
Sean Grillo, Senior Operations Manager
Cybercrime Investigations Unit (CcIU)
Office of Criminal Investigations
Beyond its international criminal investigations and liaison, OCI is a world leader in public-health law enforcement, focusing on areas such as cybercrime, transnational pharmaceutical trafficking, and fraud.
Sober Homes Investigations – Case Study
Joseph R. Kadis
Sober Homes / Public Corruption / Arson
Office of State Attorney Dave Aronberg
Illegal kickbacks and bribes in exchange for referring residents of sober homes to a substance abuse treatment center, which billed insurance carriers millions for medically unnecessary drug testing and substance abuse treatment provided to residents.
Ambulance / EMT Diversion
Diahan Underwood, CCO / CNO
Priority Ambulance
Drug diversion, unfortunately, is a real consideration within the healthcare industry. High access to a wide array of pharmaceuticals, combined with varying degrees of loose policies and safeguards has led to tampering with, abuse and false replacement of many different medications, particularly opioids and benzodiazepines.
Healthcare Facilities and Drug Diversion Training:
Creating a Culture of Compliance
William J.C. Mathews
Senior Managing Director
Guidepost Solutions
This presentation will identify trends in diversion investigations;
Identify current DEA compliance issues facing Registrants; and discuss best practices.
Friday, October 27, 2023
Pallisades Ballroom
8:00 am – 12:00 pm – General Session
Diversion Funded Terrorism; A Case Expose
Marc Gonzalez, PharmD
NADDI Associate Director, Training and Education
Promethazine with Codeine Diversion Current Trends
Trish Richardson, Agent/Investigator
Medway Drug Enforcement Agency
NADDI Executive Board
Overdose Mapping through HIDTA
CJ Alberico, Nebraska State Patrol
NADDI Executive Board
The Venue
THE NADDI ROOM BLOCK AT THE HILTON IS SOLD OUT! A FEW ROOMS REMAIN AT THE ROYAL PALMS. WE’RE WORKING TO OBTAIN ADDTIONAL ROOMS AT ANOTHER HOTEL.
Hilton Myrtle Beach Resort
10000 Beach Club Drive
Myrtle Beach, SC 29572
Special Conference Hotel Room rate $149.00 single/double
*Resort Fee waived
*Hotel parking $9.00 per day
Call Reservations at (800) 876 -0010
Request Option 4 for Royal Palms.
Identify themselves as attendees of NADDI Annual Conference
The Royal Palms is the overflow Hotel attached to the Hilton. Check-in is at the Hilton front desk for Royal Palms.
We have obtained a small room block at the Kingston Resorts. The group code is NAD.
Reservation Link Kingston Resorts | Four Timeless Myrtle Beach Oceanfront Resorts
Cancellation Policy / Refund Policy
Cancellation requests for any NADDI Conference Registration must be received in writing by emailing info@naddi.org .
Cancellations more than 30 days before the event will be charged a cancellation fee of $100.00 (or full registration amount, whichever is less) will be deducted from the refund. All refunds will be made by check and will be sent to the original payer on file.
Cancellations less than 30 days before the event will not be eligible for a refund.
Registrants wishing to cancel may instead transfer their registration to someone else without penalty if they send a written request, no later than 24 hours prior to the conference, with the replacement person’s name.
Credit vouchers may be offered in the event of a medical emergency, or should the program be suspended or shortened due to conditions or circumstances beyond NADDI’s control, including but not limited to any cancellations/modifications related to the COVID-19 epidemic.
All cancellations will be reviewed by the NADDI Board of Directors or its Designee, who in turn will recommend the appropriate refund and/or action.
Venue: Hilton Myrtle Beach
Venue Phone: 843-449-5000
Address: